During the last session, Janux Therapeutics Inc (NASDAQ:JANX)’s traded shares were 0.57 million, with the beta value of the company hitting 3.52. At the end of the trading day, the stock’s price was $54.39, reflecting an intraday gain of 0.74% or $0.4. The 52-week high for the JANX share is $65.60, that puts it down -20.61 from that peak though still a striking 89.61% gain since the share price plummeted to a 52-week low of $5.65. The company’s market capitalization is $2.84B, and the average intraday trading volume over the past 10 days was 0.69 million shares, and the average trade volume was 584.32K shares over the past three months.
Janux Therapeutics Inc (JANX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.18. JANX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.33.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Janux Therapeutics Inc (NASDAQ:JANX) trade information
Janux Therapeutics Inc (JANX) registered a 0.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.74% in intraday trading to $54.39, hitting a weekly high. The stock’s 5-day price performance is 1.83%, and it has moved by 23.14% in 30 days. Based on these gigs, the overall price performance for the year is 747.20%. The short interest in Janux Therapeutics Inc (NASDAQ:JANX) is 4.33 million shares and it means that shorts have 6.99 day(s) to cover.
The consensus price target of analysts on Wall Street is $63, which implies an increase of 13.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $42 and $70 respectively. As a result, JANX is trading at a discount of -28.7% off the target high and 22.78% off the low.
Janux Therapeutics Inc (JANX) estimates and forecasts
Statistics show that Janux Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Janux Therapeutics Inc (JANX) shares have gone down -16.04% during the last six months, with a year-to-date growth rate less than the industry average at 10.61% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -32.00% this quarter and then drop -52.00% in the quarter after that. In the rating firms’ projections, revenue will increase 65.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.64M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 1.6M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -92.62%. While earnings are projected to return 16.36% in 2024.
JANX Dividends
Janux Therapeutics Inc is due to release its next quarterly earnings on 2024-Aug-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
Janux Therapeutics Inc insiders own 8.97% of total outstanding shares while institutional holders control 96.51%, with the float percentage being 106.02%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 220.0 institutions own stock in it. As of 2024-06-30, the company held over 9.17 million shares (or 18.6864% of all shares), a total value of $383.95 million in shares.
The next largest institutional holding, with 7.78 million shares, is of FMR LLC’s that is approximately 15.8566% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $325.8 million.
